NasdaqGS:MRNABiotechs
Is Moderna (MRNA) Using Recordati To Test A Capital‑Light Blueprint For Rare Disease Growth?
Moderna has announced a collaboration and license agreement with Recordati to advance mRNA-3927 for propionic acidemia, with Moderna leading development and manufacturing while Recordati prepares to handle global commercialization if the therapy is approved.
The deal, which includes up to US$160 million in upfront and near-term milestone payments plus future milestones and royalties, underlines Moderna’s push to build a rare disease franchise beyond its COVID-19 vaccine business.
Next, we’ll...